Form 4: Gilead Executive Exercises Options, Sells Shares

Gilead Sciences' EVP of Corporate Affairs and General Counsel, Deborah H. Telman, exercised stock options and subsequently sold common stock totaling 53,646 shares under a pre-arranged trading plan.

Summary

• Deborah H. Telman, Executive Vice President, Corporate Affairs & General Counsel of Gilead Sciences, Inc. (GILD), engaged in multiple transactions on November 12, 2025.
• Telman exercised non-qualified stock options to acquire a total of 53,646 shares of common stock.
• The exercise prices for these options were $75.12 for 17,181 shares and $60.75 for 36,465 shares (35,965 + 500 shares).
• Immediately following the option exercises, Telman sold all 53,646 acquired common shares.
• The sale prices for the common stock were $124 for 17,181 shares, an average of $122.302 for 35,965 shares (ranging from $121.87 to $122.83), and an average of $122.904 for 500 shares (ranging from $122.88 to $122.92).
• All reported transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025.
• Following these transactions, Telman directly beneficially owns 43,676 shares of common stock and 62,609 non-qualified stock options.
• The stock options have a four-year vesting schedule, with 25% vesting on the first anniversary of the grant date and the balance vesting 6.25% quarterly thereafter.

Sentiment

Score: 6

Explanation: The filing reports routine insider transactions under a pre-planned 10b5-1 program, indicating an executive realizing value from compensation. This is generally neutral to slightly positive, as it reflects the executive's ability to monetize stock appreciation, without suggesting new fundamental information about the company.

Positives

• The executive is realizing value from previously granted stock options, indicating a significant increase in the company's stock price since the options were granted (exercise prices of $60.75 and $75.12 versus sale prices around $122-$124).
• The transactions were conducted under a Rule 10b5-1 trading plan, demonstrating pre-planned and compliant insider trading practices.

Negatives

• The sale of shares by an executive, even under a 10b5-1 plan, reduces their direct equity stake in the company, which some investors might interpret as a slight reduction in management's alignment with shareholder interests.

Future Outlook

NA

Industry Context

This filing details a routine executive compensation event within the pharmaceutical and biotechnology industry, where stock options are a common component of executive pay. The exercise and sale of options under a 10b5-1 plan are standard practices for executives to manage their personal finances and diversify their holdings while adhering to insider trading regulations.

Comparison to Industry Standards

• The use of a Rule 10b5-1 trading plan aligns with best practices in corporate governance for managing insider stock transactions, common among publicly traded companies like Gilead Sciences.
• The vesting schedule for the stock options (25% on first anniversary, then 6.25% quarterly) is a typical structure designed to incentivize long-term executive retention and performance, comparable to compensation structures at peer companies in the biopharmaceutical sector.

Corporate Governance

Stakeholder Impact

• Shareholders: The sale of shares by an executive, while pre-planned, slightly reduces the executive's direct equity alignment with shareholders. However, the transactions reflect the executive monetizing compensation, which is a common and expected event.

Key Dates

Recommendation

This Form 4 filing details routine, pre-planned insider transactions (option exercises and subsequent sales) by an executive. Such filings typically do not contain new material information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The transactions reflect personal financial planning and compensation realization rather than a change in the company's fundamental outlook.

Keywords

Gilead Sciences, GILD, Insider Transaction, Form 4, Stock Options, Executive Compensation, Rule 10b5-1 Plan, Deborah H. Telman